First Time Loading...
P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 16.95 CNY 0.12% Market Closed
Updated: Jun 1, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

3.3B
-3%
Assets
Growth Rates:
1 Year
-4%
3 Years
+61%
5 Years
+71%
7 Years
+88%
10 Years
-
538.3m
-12%
Liabilities
Growth Rates:
1 Year
-8%
3 Years
+69%
5 Years
+101%
7 Years
+110%
10 Years
-
2.7B
-0.4%
Equity
Growth Rates:
1 Year
-3%
3 Years
+59%
5 Years
+67%
7 Years
+84%
10 Years
-

Balance Sheet Decomposition
Pulike Biological Engineering Inc

3.3B
Assets
538.3m
Liabilities
3.3B
Assets
538.3m
Liabilities
Current Assets 1.4B
Cash & Short-Term Investments 719.4m
Receivables 489.9m
Other Current Assets 200.2m
Non-Current Assets 1.9B
Long-Term Investments 339.8m
PP&E 1.2B
Intangibles 301.2m
Other Non-Current Assets 36.5m
Current Liabilities 508m
Accounts Payable 109.9m
Accrued Liabilities 68.6m
Short-Term Debt 35.1m
Other Current Liabilities 294.5m
Non-Current Liabilities 30.3m
Long-Term Debt 1.1m
Other Non-Current Liabilities 29.3m

Balance Sheet
Pulike Biological Engineering Inc

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
214
391
429
250
438
283
240
165
282
312
Cash
0
0
0
0
0
0
0
165
282
312
Cash Equivalents
213
391
429
250
438
283
240
0
0
0
Short-Term Investments
0
400
515
700
295
319
266
75
691
408
Total Receivables
122
112
118
115
150
169
215
310
507
490
Accounts Receivables
78
109
103
109
141
129
205
292
482
439
Other Receivables
44
3
15
7
9
40
10
18
25
51
Inventory
53
60
62
71
97
118
134
171
192
184
Other Current Assets
4
3
2
15
23
23
25
14
22
17
Total Current Assets
392
966
1 125
1 152
1 003
912
880
733
1 683
1 409
PP&E Net
324
299
353
369
367
395
466
652
950
1 175
PP&E Gross
324
299
353
369
367
395
466
652
950
1 175
Accumulated Depreciation
114
140
163
192
223
285
302
324
375
447
Intangible Assets
115
231
215
208
220
220
223
276
286
283
Goodwill
0
0
0
0
0
18
18
18
18
18
Long-Term Investments
6
7
42
59
290
321
391
418
383
340
Other Long-Term Assets
1
1
2
18
23
40
52
71
75
37
Other Assets
0
0
0
0
0
18
18
18
18
18
Total Assets
838
N/A
1 504
+80%
1 737
+16%
1 805
+4%
1 903
+5%
1 906
+0%
2 029
+6%
2 168
+7%
3 396
+57%
3 262
-4%
Liabilities
Accounts Payable
31
21
28
29
43
39
45
49
123
110
Accrued Liabilities
9
13
19
27
37
43
52
60
70
69
Short-Term Debt
0
0
0
0
0
0
0
0
55
35
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
1
1
Other Current Liabilities
86
108
177
151
158
132
193
237
307
294
Total Current Liabilities
126
142
224
207
238
214
290
346
556
508
Long-Term Debt
0
0
0
0
0
0
0
0
2
1
Deferred Income Tax
0
0
0
0
2
7
11
15
25
8
Other Liabilities
29
24
32
30
28
27
18
7
8
22
Total Liabilities
154
N/A
167
+8%
256
+54%
236
-8%
268
+13%
247
-8%
319
+29%
368
+15%
592
+61%
538
-9%
Equity
Common Stock
120
160
324
324
324
322
322
321
353
353
Retained Earnings
511
604
744
794
865
888
1 053
1 139
1 239
1 188
Additional Paid In Capital
53
573
459
478
474
449
469
473
1 346
1 324
Treasury Stock
0
0
46
27
27
0
134
134
134
141
Total Equity
684
N/A
1 337
+96%
1 481
+11%
1 569
+6%
1 636
+4%
1 658
+1%
1 710
+3%
1 800
+5%
2 804
+56%
2 724
-3%
Total Liabilities & Equity
838
N/A
1 504
+80%
1 737
+16%
1 805
+4%
1 903
+5%
1 906
+0%
2 029
+6%
2 168
+7%
3 396
+57%
3 262
-4%
Shares Outstanding
Common Shares Outstanding
240
320
320
324
324
322
322
315
346
346

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 142,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.